| Pharmacokinetics of amikacin in plasma of healthy goats after intravenous injection once daily for three days |
|
Sania Naseem1, Mudasir Sultana1, Rajinder Raina1, Nrip Kishore Pankaj1, Pawan Kumar Verma1, Nasir Ahmad Nasir1, Azad Ahmad Ahanger2, Shafiqur Rahman3, Shahid Prawez1 |
1Divisions of Pharmacology and Toxicology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-J
2Division of Pharmacology and Toxicology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir
3Divisions of Veterinary Pathology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-J |
|
|
| Abstract |
|
Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gram-negative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and noncompartmental open-model, respectively. The mean peak plasma concentrations (Mean ${pm}$ SD) of amikacin at time zero ($Cp^{0}$) was $114.19{pm}20.78$ and $128.67{pm}14.37{mu}g/mL$, on day 1st and 3rd, respectively. The mean elimination half-life ($t_{1/2}ke$) was $1.00{pm}0.28h$ on day 1st and $1.22{pm}0.29h$ on day 3rd. Mean of area under concentration-time curve ($AUC_{0{
ightarrow}{infty}}$) was $158.26{pm}60.10$ and $159.70{pm}22.74{mu}g.h/mL$, on day 1st and 3rd respectively. The total body clearance ($Cl_{B}$) and volume of distribution at steady state (Vdss) on day 1st and 3rd were $Cl_{B}=0.07{pm}0.02$ and $0.06{pm}0.01L/h.kg$ and $Vdss=0.10{pm}0.03$ and $0.11{pm}0.05L/kg$, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokinetic-pharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens. |
| Key Words:
amikacin, intravenous bolus injection, pharmacokinetics, three days, 10 mg/kg |
|
PDF Links
Full text via DOI
Download Citation
